MydCombi. Eyenovia’s FDA-approved proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for pupil dilation.
With MydCombi™, practices could potentially replace the current standard of care of 3 drops (anesthetic, tropicamide, phenylephrine). In clinical trials with MydCombi, less than 1% of subjects reported an AE of stinging , while still achieving effective pupil dilation1. MydCombi has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery. Plus, with no protruding parts and a recessed nozzle, the Optejet® is less likely to touch the eye of patients, compared to an eyedropper.
Disease State.
MydCombi is Eyenovia’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation. In the United States alone, there are an estimated 104 million eye exams performed annually which require pupil dilation2. Another 4 million dilations are performed for cataract surgery2.
Standard of Care (SOC).
The current mydriatic practice is to administer several conventional eyedrops sequentially. Typically, the patient is given a drop of anesthetic followed by separate drops of tropicamide and phenylephrine. Unfortunately, as the volume of a drop exceeds that of the capacity of the eye, patients often experience overdosing and overflow3.
Eyenovia Innovation.
To raise the standard of care, improve the overall patient experience and streamline practice flow, Eyenovia has developed an innovative mydriatic to be delivered as a microdose by a specialized dispenser. In clinical trials with MydCombi, approximately 94% of treated eyes achieved 6mm or greater dilation at 35 minutes post-installation less than 1% of subjects reported an AE of stinging1.
While still achieving effective pupil dilation, MydCombi has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery. Plus, with no protruding parts and a recessed nozzle, the Optejet less likely to touch the eye of patients, compared to an eyedropper.
1. Wirta, David. 2019, April. Two Phase 3 Studies Of The Safety And Efficacy Of Fixed Combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution.
2. The State of the Optometric Profession (Jobson Medical Information, 2013).
3. American Academy of Ophthalmology (AAO). “Wouldn’t it be great if eyedrops didn’t spill out of your eyes?.” ScienceDaily. ScienceDaily, 13 November 2017.